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difference is usually called attributable risk. For coronary heart 
disease risk factors, the absolute attributable risk increases 
often markedly with age, whereas the relative risk may, in fact, 
decrease. For example, the relative risk of stroke due to 
hypertension is smaller in the elderly than in middle age, but 
among 100 treated patients, older patients will receive more 
absolute benefits from treatment than middle-aged adults. 
Nonetheless, for common and serious diseases, such as heart 
disease and stroke, a small alteration in relative risk will have 
an important clinical and public health impact. 
The strength of one risk factor in the presence of another 
may be greater than the sum of the strengths of the individual 
factors. For example, women of childbearing age who use 
oral contraceptives have about twice the risk of myocardial 
infarction than nonusers. In addition, women of childbearing 
age who smoke have about 13 times the risk of myocardial 
infarction than nonsmokers. However, women of childbearing 
age who both use the pill and smoke have about 40 times the 
risk of myocardial infarction compared to those who do 
neither. Finally, given the risk and prevalence of oral contra- 
ceptives and cigarette smoking in the U.S. population, oral 
contraceptives accounts for almost 400 deaths each year, 
whereas cigarette smoking accounts for 400,000 deaths each 
year. 
Points to remember:. 
1. In assessing a risk factor, one can reasonably conclude 
the presence or absence of a valid statistical association, having 
considered the possible roles of chance, bias and confounding 
as alternative explanations. 
2. In making a judgment about a cause and effect relation- 
ship, one must consider not simply the results of a single study, 
but the totality of the evidence from all studies. Furthermore, 
criteria that increase belief in causality include strength of 
association, temporal sequence, dose-response, consistency, 
biologic plausibility and specificity. 
3. Risk can be measured in relative or absolute terms. 
Whereas high relative risks increase the likelihood of a cause/ 
effect relationship, high absolute attributable risks identify the 
public health consequences and value of treatment. 
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Understanding the concept of risk and risk factors is central to 
the evaluation of the hazard for coronary disease events and 
essential for appropriate clinical decision making with respect 
to the management of specific factors associated with coronary 
disease risk. The notion of risk is not new, but the idea that 
specific factors serve as markers of the level of risk has arisen 
relatively recently, largely as a result of population-based 
studies such as the Framingham Heart Study. Critical to our 
JACC gol. 27, No. 5 PASTERNAK ET AL. 979 
April 1996:964-1047 TASK FORCE 3 
understanding is the sometimes tenuous relationship between 
risk factors and causality. The importance of a risk factor ests 
on three fundamental relations: 1) the biologic connection 
between the factor and the atherosclerotic process (see Task 
Force 1); 2) the statistical strength of its association with future 
cardiovascular disease vents, often termed its "relative risk" 
(see Task Force 2); and 3) the extent o which changes in the 
factor have been shown to influence the future clinical course. 
Such changes can be observed, as with age, or produced with 
an intervention, as with low density lipoprotein (LDL) choles- 
terol. 
Risk Factor Categories 
Risk factors have been categorized by several properties, 
including modifiable versus nonmodifiable, life-style versus 
biochemical/physiologic, continuous versus dichotomous, indi- 
vidual versus population, causal versus associative, chronic 
versus acute and others. 
For the present purpose, namely, matching management 
intensity with cardiovascular risk, we propose ascheme divided 
into categories of descending levels of evidence to support direct 
management. That is, we propose to begin with those risk 
factors for which the most conclusive evidence exists and 
whose management favorably affects outcome, and we end with. 
those factors for which there are no direct management 
opportunities or for which modification would be unlikely to 
affect he course of disease (the presence of such factors may, 
however, lead to more intense management of other risk 
factors). By focusing on management priorities, categorized by 
evidence of treatment efficacy, we recognize that for the 
purposes of this Bethesda Conference, causality is of secondary 
importance. Therefore, for example, diabetes falls into cate- 
gory II because, despite our knowledge of its causal role in 
atherosclerosis, the benefit of treatment in lowering vascular 
risk is less well established. Conversely, thrombogenic factors 
fall into category I because of abundant evidence supporting 
the benefit of treatment and the magnitude of this treatment 
effect even though identification of a specific prothrombotic 
factor is often lacking. 
Proposed risk factor categories: 
I. Risk factors for which interventions have been proved to 
reduce the incidence of coronary artery disease vents. 
II. Risk factors for which interventions are likely, based on 
our current pathophysiologic understanding and on epidemi- 
ologic and clinical trial evidence, to reduce the incidence of 
coronary artery disease vents. 
III. Risk factors clearly associated with an increase in 
coronary artery disease risk, and which, if modified, might 
lower the incidence of coronary artery disease vents. 
IV. Risk factors associated with increased risk but which 
cannot be modified or whose modification would be unlikely to 
change the incidence of coronary disease vents. 
For more than 50 years, research as suggested that diet is 
a, if not the, major environmental cause of coronary athero- 
sclerosis. Within populations, a diet high in saturated fat, 
cholesterol and calorie content is widely recognized to exacer- 
bate many of the traditional risk factors, including dyslipide- 
mia, obesity and diabetes. Dietary sodium is important in 
hypertensive patients. More recently, intake of foods high in 
antioxidants, folate, vitamins B6 and B12 and soluble fiber have 
been suggested to lower coronary artery disease risk. Con- 
sumption of different unsaturated fatty acids (e.g., transfatty 
acids, marine oils) also affects risk. Because dietary modification 
is of importance throughout the course of evaluation and man- 
agement of many of the major risk factors, an imprudent "diet" 
itself has not been included in the list of risk factors as 
categorized below. Rather, diet is seen to interact with many 
different risk factors at many different levels. Were diet to be 
included as a single factor, it would qualify for category I 
status. 
Category I: Risk Factors for Which 
Interventions Have Been Proved to Reduce the 
Incidence of Coronary Artery Disease Events 
Cigarette smoking. The evidence that cigarette smoking 
increases the risk for cardiovascular disease is based on observa- 
tional studies, is overwhelming and is considered proved by 
the Task Force (1). The cardiovascular risk of smoking was 
appreciated as early as the middle of this century (2). The 
Surgeon General's report in 1964 established this epidemio- 
logic relationship (3), and the 1989 Surgeon General's report 
presented efinitive data from observational case-control and 
cohort studies that showed that smoking increased cardiovas- 
cular mortality by 50% and essentially doubled the incidence of 
cardiovascular disease (4). Importantly, a linear relation exists 
between cardiovascular risk and cigarettes consumed (5), with 
relative risks approaching 5.5 for fatal cardiovascular events 
among heavy smokers compared with nonsmokers (6). Smok- 
ing accelerates the atherogenic process in both a duration- and 
dose-dependent fashion. In one study of women, cigarette 
smoking accounted for half of all coronary disease deaths (7). 
An average smoker dies 3 years earlier than a nonsmoker, and 
a person known to be at "high risk" for coronary disease dies 
10 to 15 years earlier if he or she smokes (8,9). Smoking 
amplifies the effect of other risk factors, thereby accelerating 
atherosclerosis and influencing the production of acute cardio- 
vascular events (10). Dietary factors, hyperlipidemia and hy- 
pertension markedly increase the effect of cigarette smoking 
on coronary artery disease mortality and morbidity. In partic- 
ular, events related to thrombus formation, plaque instability 
and arrhythmias are all influenced by cigarette smoking. 
Clinical data accumulated over the past 20 years strongly 
suggest that smoking cessation reduces the risk of cardiovas- 
cular events (11). Prospective cohort studies how that the risk 
of myocardial infarction declines more rapidly than overall 
death from cardiovascular disease, with the greatest propor- 
tion of risk reduction occurring in the first several months after 
cessation. A number of studies have demonstrated that pa- 
tients who continue to smoke after acute myocardial infarction 
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have an increase in the risk of death and reinfarction. The 
increase in risk of death has ranged from 22% to 47%. 
Paradoxically, many studies of acute mortality with myocardial 
infarction have found better survival in smokers than in 
nonsmokers. These results eem to emanate from the younger 
age of smokers when they have an acute event, coupled with 
their lesser underlying atherosclerosis at the time of the acute 
event. Smoking has been clearly implicated in bypass graft 
atherosclerosis and thrombosis. Continued smoking after by- 
pass grafting is associated with a twofold increase in the 
relative risk of death and an increase in nonfatal myocardial 
infarction and angina. 
Environmental exposure to second-hand smoke also poses 
considerable risk. It is estimated that passive smoking causes 
almost 40,000 heart disease deaths yearly in the United States. 
This exposure isthe third leading cause of preventable death in 
this country (12). A degree of "conditioning" may compensate 
for some of the effects of chronic smoking among regular 
smokers, but this is less active among those with passive 
exposure to smoke. Paradoxically, it is possible that the risk of 
passive smoking may actually be even greater in individuals not 
preconditioned by habitual smoke exposure (12). 
Low density lipoprotein cholesterol. Total blood choles- 
terol is conclusively linked to the development of coronary 
artery disease vents, with a continuous and graded risk down 
to a total cholesterol <180 mg/dl (13,14). Most of this risk is 
explained by the LDL cholesterol concentration. Therefore, 
this document focuses on LDL cholesterol rather than total 
cholesterol. The evidence linking LDL cholesterol and coro- 
nary artery disease is derived from extensive pidemiologic, 
laboratory and clinical trial data. Low density lipoprotein is the 
lipoprotein most strongly associated with risk for coronary 
heart disease in epidemiologic studies. In general, these studies 
indicate a 2% to 3% difference in risk for coronary heart 
disease per 1% difference in LDL cholesterol level (15). In 
population studies, LDL cholesterol parallels changes in total 
cholesterol, whereas in individual subjects the relationship is 
not always tight. Thus, there is a need for measurement of
LDL cholesterol levels in high risk patients. In the United 
States, the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel II has stratified the risk of LDL levels 
as follows: LDL cholesterol ->160 mg/dl is "high risk LDL 
cholesterol"; 130 to 159 mg/dl is "borderline high risk LDL 
cholesterol"; and <130 mg/dl is a "desirable LDL cholesterol" 
(15). The LDL cholesterol increases with age and is also 
increased by weight gain and diets high in saturated fat and 
cholesterol. Genetic factors further contribute to the variation 
in LDL cholesterol levels in the general population. Levels of 
LDL may be increased in chronic hypothyroidism, the ne- 
phrotic syndrome, certain liver diseases, estrogen deficiency 
and dysglobulinemia. Certain constellations of lipids appear to 
increase overall risk synergistically. Elevated LDL cholesterol, 
elevated triglycerides and low high density lipoprotein (HDL) 
cholesterol levels constitute a particularly adverse risk profile, 
as reported in the Helsinki Heart Study (16) and the Prospec- 
tive Cardiovascular MOnster (PROCAM) study (17). 
Table 1. Classification of Blood Pressure for Adults 18 Years 
and Older* 
SBP DBP 
Category (ram Hg) (mm Hg) 
Normal <130 <85 
High normal 130-139 85-89 
Hypertensiont 
Stage 1 (mild) 140-159 90-99 
Stage 2 (moderate) 160-179 100-109 
Stage 3 (severe) 180-209 110-119 
Stage 4 (very severe) ->210 ->120 
*When systolic (SBP) and diastolic blood pressures (DBP) fall into different 
categories, the higher category should be selected to classify the subject's blood 
pressure status, tBased on the average of two or more readings taken at each of 
two or more visits after initial screening. Reprinted with permission from the 
National Heart, Lung, and Blood Institute, National Institutes of Health, 
Bethesda, Maryland. The Fifth Report of the Joint National Committee on 
Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern 
Med. 1993;153:154-83. 
Several recent reports indicate that therapeutic lowering of 
LDL cholesterol levels is highly effective in secondary preven- 
tion. Angiographic studies how that reduction of LDL levels 
can delay progression of coronary atherosclerosis and in some 
cases, promote regression of lesions. However, of even greater 
importance, these trials demonstrate hat LDL lowering pro- 
duces a striking reduction in acute coronary events (unstable 
angina pectoris and acute myocardial infarction). These ben- 
eficial outcomes have now been observed in a meta-analysis of 
earlier secondary prevention trials (18), in angiographic trials 
(19) and in the recently reported Scandinavian Simvastatin 
Survival Study (20). In the latter study, LDL lowering induced 
by an HMG-CoA reductase inhibitor reduced coronary mor- 
tality by 42% and total mortality by 30%. Thus, studies of 
several types have demonstrated the benefit of LDL lowering 
in secondary prevention, probably by reducing the risk for 
plaque rupture. 
Clinical trials also demonstrate b nefit from LDL lowering 
in primary prevention, as indicated by the recent West of 
Scotland Study (21). However, the number of infarctions and 
deaths are less dramatic than for secondary prevention because 
patients are not at the same high risk as those with established 
coronary artery disease. Nonetheless, even in primary preven- 
tion trials, the data indicate that a 1-mg/dl owering of LDL 
cholesterol levels results in an approximate 1% to 2% reduc- 
tion in relative risk for coronary artery disease. 
Hypertension, Although "cut points" for classification of 
abnormally elevated levels of blood pressure (Table 1) have 
been established, data from numerous studies indicate a 
continuous relationship between systolic and diastolic arterial 
pressure and cardiovascular risk (22,23). Evidence of target 
organ involvement at relatively modest levels of hypertension 
has recently led to a reclassification from the traditional 
"mild-moderate-severe" to four specific "stages" of hyperten- 
sion (24). Both the level of blood pressure and markers of 
end-organ damage are used clinically in the estimation of 
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hypertension severity. Specifically, left ventricular hypertrophy 
(as discussed later), retinopathy and decreased renal function, 
all of which occur as a consequence of hypertension, are 
themselves independent markers of cardiovascular risk. Thus, 
like diabetes mellitus, hypertension is both a risk factor and a 
"disease." 
Nearly 50 million adult Americans, roughly 30% of U.S. 
adults, have hypertension. It is more prevalent in African- 
Americans and increases with age. In populations with coro- 
nary artery disease, the incidence of hypertension is as much as 
three times higher in African-Americans than in other ethnic 
groups (25,26). Hypertension also appears to be more severe in 
blacks, who have a fivefold higher incidence of severe hyper- 
tension (diastolic blood pressure ->115 mm Hg) than whites. 
Epidemiologically, the risk of hypertension has often been 
difficult to evaluate independent of its strong association with 
other risk factors, including physical inactivity, obesity, alcohol 
and sodium consumption and psychological issues. A meta- 
analysis by MacMahon and colleagues (27) of nine prospective, 
observational studies involving over 400,000 participants 
showed a strongly positive relationship between both systolic 
and diastolic blood pressure and coronary heart disease; the 
relationship was linear, without a threshold effect, and showed 
a relative risk that approached 3.0 at the highest pressures. The 
presence of such additional factors appears to be both partially 
causal for hypertension (e.g., weight gain predisposes to ele- 
vations in blood pressure) and additive (physical inactivity and 
hypertension together confer much higher cardiovascular risk 
than either alone). The mechanism whereby hypertension 
increases coronary events results from both the direct vascular 
injury caused by increases in blood pressure and from its effects 
on the myocardium, including increased wall stress and myo- 
cardial oxygen demand. 
There is considerable vidence that reducing blood pres- 
sure decreases the development of cardiovascular disease 
events, including coronary artery disease, stroke and heart 
failure. The reduction in coronary artery disease events in 
these studies has often been less than that expected from the 
magnitude of blood pressure reduction. This observation 
should neither diminish acceptance of the causal role of 
hypertension i  the production of coronary artery disease 
events or in the importance of its treatment; but it has called 
attention to both the potentially proatherogenic effects of 
certain antihypertensive tr atments ( uch as the unfavorable 
lipid effects of thiazides) and to the possible consequences of 
excessive blood pressure lowering once severely stenotic oro- 
nary or peripheral vascular disease is established. 
Left ventricular hypertrophy. Left ventricular hypertrophy 
is the response of the heart to chronic pressure or volume 
overload, or both. Its prevalence and incidence are higher with 
increasing levels of blood pressure (28). For over a quarter of a 
century, epiderniologic studies have implicated left ventricular 
hypertrophy as a risk factor for the development of cardiovascular 
disease, including myocardial infarction, congestive heart failure 
and sudden death (29,30). Earlier studies documenting the haz- 
ards associated with left ventricular hypertrophy were based on its 
detection on the electrocardiogram (ECG). Echocardiography 
now provides an autopsy validated, noninvasive method for 
quantifying left ventricular mass. The use of echocardiography 
in epidemiologic studies has resulted in an increased appreci- 
ation of the role of left ventricular hypertrophy as a precursor 
of coronary artery disease (31). Its association with increased 
risk has been described in hospital- and clinic-based studies 
(32-34) and in population studies (31,35,36). 
There is a growing body of evidence in hypertensive pa- 
tients that regression of left ventricular hypertrophy can occur 
in response to pharmacologic and nonpharmacologic (37,38) 
antihypertensive tr atment. Recent data suggest hat regres- 
sion of left ventricular hypertrophy can reduce the cardiovas- 
cular disease burden associated with this condition. A report 
from the Framingham Heart Study found that subjects who 
demonstrated ECG evidence of regression of left ventricular 
hypertrophy were at substantially reduced risk for a cardiovas- 
cular event (39) compared to subjects who did not. There are 
no large-scale echocardiographic studies documenting the 
prognostic implications of regression of left ventricular hyper- 
trophy, and no intervention trials targeting regression of left 
ventricular hypertrophy, rather than blood pressure control, 
have prospectively demonstrated a benefit of regression of left 
ventricular hypertrophy. Such studies have been planned and 
are needed to definitively establish the direct benefits of 
regression of left ventricular hypertrophy. 
Thrombogenic factors. Coronary thrombosis i present in 
most cases of acute myocardial infarction. Aspirin has been 
documented to reduce both primary and secondary coronary 
heart disease vents, demonstrating that reduction of "throm- 
bogenic" risk improves outcome (40). A number of prothrom- 
botic factors have been identified and can be quantified (41). 
Some factors can be changed by pharmacologic and behavioral 
treatments. However, the treatment of any single variable has 
not been shown to lower coronary, disease risk. Thrombogenic 
factors are included in this category because antithrombotic 
treatment i self has been established tolower risk. Thus, in the 
case of thrombogenic factors, we know that treatment affects 
risk, but often we do not know which specific abnormalities are 
being treated. 
The importance of thrombogenic factors is further sug- 
gested by observations that only one-third of acute myocardial 
infarctions can be accounted for by other risk factors, such as 
elevated lipid levels, smoking and hypertension (42). Further- 
more, a wide variety of clinical conditions known to affect 
coagulability are accompanied by increased risk of vascular 
thrombosis. In some cases, these conditions are associated with 
the production of specific prothrombotic substances, uch as 
antiphospholipid antibody in systemic lupus erythematosus 
and homocysteine in homozygous homocystinuria. Deficien- 
cies of serum coagulation inhibitors (e.g., antithrombin III, 
protein C and protein S) have also been shown to predict 
thrombotic events, although this has been shown more conclu- 
sively for venous as opposed to arterial disease. Treatment of 
these specific abnormalities generally lowers the risk for 
thrombotic vascular events. 
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The production of a coronary thrombus is stimulated by 
both local factors leading to plaque disruption and hemostasis, 
and by an imbalance between factors favoring clot formation 
and those favoring clot lysis. This balance varies in a circadian 
fashion, with diurnal variation in the incidence of myocardial 
infarction, stroke, sudden death and silent ischemia (43). The 
complexity of the clotting cascade and the endogenous throm- 
bolytic systems makes it clear that a variety of individual 
factors could be responsible for the enhancement of a throm- 
botic state. In general, large observational epidemiologic stud- 
ies have identified constellations of thrombotic factors (see 
later) associated with an increased risk for coronary artery 
disease events (44,45). However, it remains uncertain how 
much the elevated levels of prothrombotic factors are markers 
of underlying vascular disease rather than primary abnormal- 
ities themselves. As with other factors, there appears to be a 
strong interactive ffect when other major risk factors are 
present as well. Increased cholesterol, in particular, enhances 
the risk for coronary artery disease vents among patients with 
abnormal hemostatic factors (46). 
Except in the presence of a rare specific disease, such as 
protein C deficiency, there are no cost-effective tests or 
measures of the prothrombotic state. Thus, in the case of this 
risk factor, treatment of thrombogenic risk is generally under- 
taken without identification of the individual factor responsi- 
ble. Although much attention has been directed at identifying 
specific thrombogenic abnormalities, direct specific treatment 
has not yet been shown to alter risk, as discussed later. 
Elevated plasma fibrinogen levels predict coronary artery 
disease risk in prospective observational studies (47). The 
increase in risk related to fibrinogen is continuous and graded 
(48). Patients in the upper tertile of fibrinogen distribution 
have more than a twofold increase in risk for coronary events 
compared with the lower tertile. In the presence of total 
cholesterol or LDL cholesterol elevations, high fibrinogen 
levels increase coronary heart disease risk more than sixfold 
(46). Low fibrinogen levels appear to offer protection, even in 
the presence of high total cholesterol levels (49). The predic- 
tive power of an elevated fibrinogen level appears to be 
independent ofother risk factors. However, elevated triglycer- 
ides, smoking and physical inactivity all are associated with 
increased fibrinogen levels. Exercise and smoking cessation 
appear to favorably alter fibrinogen levels, as do fibric acid- 
derivative drugs. Reducing fibrinogen levels could lower risk by 
improving plasma viscosity and myocardial oxygen delivery and 
by diminishing the risk of thrombosis (41). Anticoagulant or 
antiplatelet therapy may reduce the effect of an elevated 
fibrinogen level by blocking its impact on the coagulation 
system, even though these agents do not lower the level of 
fibrinogen itself. 
Several studies support a positive relationship between 
platelet aggregability and vascular disease, a finding consistent 
with the known role of platelets in thrombosis and coronary 
artery disease vents (41). Measures of platelet hyperaggrega- 
bility, including the presence of spontaneous platelet aggrega- 
tion (50) and increased platelet aggregability induced by 
conventional stimuli (51), increase risk in both cohort and 
cross-sectional studies. Although the benefit of aspirin therapy 
in primary and secondary prevention has been clearly estab- 
lished, this has not yet been etiologically linked to the reversal 
of specific platelet abnormalities. 
Factor VII is a procoagulatory, vitamin K-dependent pro- 
tein. High levels of Factor VII coagulant (VIIc) activity are 
associated with increased coronary artery disease risk in pro- 
spective observational studies (45). The level of Factor VIIc is 
influenced by dietary saturated fat intake and by estrogen use 
(52). Support for the role of Factor VII is also provided by 
evidence that it is rapidly affected by oral anticoagulants, which 
have been shown to lower the risk of myocardial infarction in 
prospective randomized trials (53). 
Other hemostatic factors of possibly causal importance 
include plasminogen activator inhibitor-1 antigen, tissue-type 
plasminogen activator (t-PA) antigen, yon Willebrand factor, 
C-reactive protein, protein C and antithrombin III levels 
(41,54). It is probable that anticoagulants affect several of these 
factors, partially explaining their influence on decreasing cor- 
onary artery disease risk. 
Category II. Risk Factors for Which 
Interventions Are Likely to Lower Coronary 
Artery Disease Events 
Diabetes mellitus. The relationship between diabetes and 
athcrosclerotic risk is complex. Strong epidemiologic and 
clinical evidence indicates that diabetes mellitus is a major risk 
factor for coronary artery disease. This is true for both 
insulin-dependent diabetes mellitus (IDDM) and non-insulin- 
dependent diabetes mellitus (NIDDM). Atherosclerosis ac- 
counts for 80% of all diabetic mortality (55-57). Coronary 
artery disease alone is responsible for 75% of total atheroscle- 
rotic deaths; the remainder results from an admixture of stroke 
and peripheral vascular disease. Coronary mortality is in- 
creased threefold to tenfold in patients with Type I IDDM 
compared with that in age-matched nondiabetic ontrol sub- 
jects. In patients with Type II NIDDM, coronary mortality is 
increased 200% in male and 400% in female patients. The 
National Cholesterol Education Program estimates that 25% 
of all heart attacks in the United States occur in patients with 
diabetes (58,59). 
Because the metabolic abnormalities among different types 
of diabetic patients and different individual diabetic subjects 
vary considerably, it is difficult to match the "intensity" of this 
risk factor with its level of risk. For example, NIDDM, despite 
lesser degrees of hyperglycemia, may induce greater cardiovas- 
cular risk than IDDM (10). Other factors accompanying 
NIDDM (e.g., insulin resistance, hyperinsulinemia and dyslip- 
idemia) may contribute to the increase in coronary disease risk 
associated with this form of diabetes. In addition, knowledge 
that patients with IDDM are at heightened risk for coronary 
artery disease suggests a pathogenetic role for hyperglycemia 
as well. Support for this role comes from the observation that, 
JACC Vol. 27, No. 5 PASTERNAK ET AL. 983 
April 1996:964-1047 TASK FORCE 3 
among patients with IDDM, better metabolic ontrol appears 
to lower vascular risk, whereas this has not been clearly shown 
for NIDDM (60,61). 
Some studies suggest hat premenopausal women with 
diabetes have an absolute risk similar to that of men of the 
same age; if so, the protection against coronary disease af- 
forded by the premenopausal state may be reduced (62,63). 
Other studies, however, are not in agreement with this claim, 
and thus, diabetic women may still enjoy some protection 
against coronary artery disease (59,64). 
Regardless of the underlying metabolic abnormalities, the 
National Diabetes Data Group (65) defines diabetes as a 
fasting blood sugar greater than 140 mg/dl. This abnormality is
present in approximately 10% of adult Americans (66). In 
clinical practice, routine oral glucose tolerance testing is less 
often performed than in the past, whereas measurement of
glycohemoglobin concentrations is often employed instead as 
an assessment of long-term (6 to 8 weeks) glucose control and 
as a marker of the diabetic state. 
Difficulty in understanding the relative risk due to diabetes 
is most likely due to at least two general factors: 1) the extent 
to which other metabolic and vascular abnormalities are 
present, especially those which also independently increase 
coronary artery disease risk (e.g., lipids and blood pressure), 
and 2) the extent to which the diabetic disorder is due to 
inadequate insulin secretion versus inadequate insulin action 
(i.e., insulin resistance). For example, in IDDM the presence 
of renal complications, as measured by proteinuria, appears to 
lead to blood pressure and lipid changes, which in turn 
increase coronary artery disease risk (67). Other factors in the 
diabetic patient that increase coronary artery disease risk 
include increased triglyceride and low HDL cholesterol levels, 
increased insulin concentrations, central adiposity and hyper- 
tension. 
Diabetes remains arisk factor for poor outcome in patients 
with established coronary artery disease, even after angio- 
graphic and other clinical characteristics are considered. In the 
long-term follow-up data from the Coronary Artery Surgery 
Study (CASS), patients with diabetes had a 57% increase in 
risk of death after controlling for other known risk factors. 
After acute myocardial infarction, patients with diabetes have 
a higher risk of death and other complications. Diabetes has 
been consistently identified as a risk factor for poor long-term 
outcome after bypass urgery. In particular, the risk increases 
after the acute recovery from the operation. The Diabetes 
Control and Complications Trial (60) convincingly demon- 
strated that improved glucose control prevents the microvas- 
cular complications of IDDM; a reduction in macrovascular 
complications was probable as well. The role of glucose control 
in NIDDM is untested. 
Physical inactivity. Physical inactivity has recently become 
a major target of preventive medicine in the United States 
(68). Approximately 12% of all mortality in the United States 
may be related to lack of regular physical activity, and physical 
inactivity is associated with at least a twofold increase in risk 
for coronary artery disease vents (69). It is difficult o measure 
physical activity, and consequently, it is difficult to quantify the 
relationship between the amount of exercise and coronary 
heart disease risk. Nevertheless, over 50 studies have estab- 
lished that physical activity, either on the job or during leisure 
time, reduces the risk of coronary artery disease events, 
particularly in men (70-72). The overall reduction in coronary 
artery disease vents persists despite asmall transient increase 
in the risk of myocardial infarction or sudden death that occurs 
during physical activity (73,74). Reduction in risk appears 
greatest between onactive and moderately active individuals. 
Less benefit occurs with increases from moderate to extreme 
amounts of total energy expenditure (69,71,75), Although any 
activity appears to be of benefit, those activities of higher 
intensity (->7 kcal/min), such as brisk walking or heavy garden- 
ing, appear to be more protective (42,76,77). 
Exercise probably exerts its beneficial effect through a 
variety of direct and indirect mechanisms (78). Physical train- 
ing improves the myocardial supply/demand relationship, low- 
ers triglycerides and raises HDL cholesterol, owers blood 
pressure, decreases platelet aggregation and improves other 
clotting factors. Furthermore, a lower rate of sudden death 
among those who exercise regularly is consistent with some 
animal studies uggesting improved myocardial electrical sta- 
bility. Studies of exercise in both animals (79) and humans (80) 
with established coronary atherosclerosis demonstrate slowing 
of atherosclerotic progression, and in some circumstances, 
actual reversal of the process occurs. 
Although no single trial of physical activity in patients with 
coronary artery disease has had sufficient power to convinc- 
ingly demonstrate a risk reduction, intermediate end points 
(e.g., HDL cholesterol and blood pressure) (70) are regularly 
improved, and several meta-analyses of randomized trials 
support a powerful (20% to 30%) reduction in coronary 
disease deaths with regular aerobic exercise (81,82). Interest- 
ingly, no reduction in nonfatal myocardial infarctions eems to 
occur .  
High density lipoprotein cholesterol. There is a strong 
inverse epidemiologic association between HDL cholesterol 
and coronary artery disease risk. This relationship is main- 
tained over a wide range of HDL levels, and it is estimated that 
for every 1-mg/dl decrease inHDL cholesterol, the relative risk 
for coronary disease vents increases by 2% to 3% (83). The 
relationship appears to be equally strong in men and women 
and among asymptomatic individuals as well as patients with 
established coronary disease. Some, but not all, genetic defi- 
ciencies of HDL or apolipoprotein A-I, the main apolipopro- 
tein in HDL, are associated with premature atherosclerosis, 
and high HDL levels have been associated with longevity in 
some studies. 
High density lipoprotein cholesterol levels are strongly 
influenced by family history and by certain life-style factors 
that in themselves are also risk factors (including cigarette 
smoking, obesity and physical inactivity). Frequently, but not 
invariably, low HDL levels are accompanied by high levels 
of triglycerides due to the close metabolic relationship involv- 
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ing cholesterol ester transfer between HDL particles and 
triglyceride-rich lipoproteins. 
Because many lipid-active agents and life-style changes 
affect multiple lipids simultaneously, it has been difficult to 
demonstrate that increasing HDL cholesterol independently 
lowers coronary heart disease risk. No completed trial has been 
able to address the efficacy of raising HDL cholesterol alone; 
several are under way. The observation i the Helsinki Heart 
Study that the reduction in coronary artery disease with 
gemfibrozil exceeded that expected from the LDL changes 
alone has been interpreted to indicate a therapeutic benefit 
from increasing HDL (16). However, there is no consensus on 
this interpretation of the Helsinki Heart Study results. The 
Adult Treatment Panel II has identified an HDL cholesterol 
<35 mg/dl as "low" and considers the presence of high HDL 
cholesterol a "negative" risk factor (15). 
Obesity. There is a linear relationship between body mass 
and mortality (84). Twenty percent of Americans between 25 
and 34 years of age are classified as obese, and approximately 
10% of the population becomes obese with each succeeding 
decade up to the age of 55 (85). 
Obesity is associated with other risk factors, including 
hypertension, glucose intolerance, and decreased HDL and 
increased triglyceride concentrations. Much of the increased 
coronary artery disease risk associated with obesity is mediated 
by these associations. Visceral or central abdominal obesity, 
which can be quantified by the waist to hip ratios, is a common 
form of moderate obesity associated with a particular pattern 
of insulin resistance and hypertension. This pattern has been 
shown to markedly increase coronary disease risk (86). It 
appears that the desirable waist to hip ratio is <0.9 for men 
and 0.8 for middle-aged women (87,88). No study has specif- 
ically examined the effect of weight loss or the type of weight 
loss on coronary artery disease vents. Obesity is included as a 
class II risk factor because of the probability that weight 
reduction will beneficially alter other important risk factors, 
often markedly so. 
Postmenopausal tatus. Although coronary artery disease 
presents about a decade later in women compared with men, 
cardiovascular disease is nevertheless the leading cause of 
death among U.S. women. The observation that the protection 
conferred upon women appears to be lost after natural meno- 
pause, and that coronary disease risk clearly increases after 
surgical menopause, supports the concept hat endogenous 
estrogen protects women against vascular injury (89,90). 
Evidence of the beneficial effects of postmenopausal estro- 
gen replacement are derived almost entirely from observa- 
tional studies. Case-control and cohort studies suggest hat 
estrogen replacement results in a 50% reduction in the risk of 
developing coronary disease (91,92) and an even greater isk 
reduction for subsequent coronary events among women with 
established coronary artery disease (93). Exogenous estrogen 
favorably affects both HDL and LDL cholesterol, although it 
modestly elevates erum triglycerides. When lipid levels are 
factored into a multivariate analysis, the protective ffect of 
exogenous estrogen appears to diminish by about half, suggest- 
ing that nonlipid factors, including probable direct effects of 
estrogen on the vessel wall, may produce some of estrogen's 
benefit (89). However, these data are observational, and 
women on postmenopausal hormone therapy may be particu- 
larly conscientious about their health and employ other risk- 
reducing behaviors not accounted for by observational studies. 
Accordingly, proof of the protective ffect of postmenopausal 
hormone replacement therapy awaits prospective clinical trials, 
including the Women's Health Initiative. These results will not 
be available for the next decade. 
Category III. Risk Factors Clearly Associated 
With an Increase in Coronary Artery Disease 
Risk, Which, If Modified, Might Lower the 
Incidence of Coronary Artery Disease Events 
Psychosocial factors. As specific risk factors become more 
difficult to objectively quantify or to reverse with specific 
interventions, proof that their treatment lowers risk becomes 
increasingly difficult to demonstrate, regardless of the impor- 
tance of the factor itself. Thus, demonstration that improve- 
ment in psychosocial factors lowers coronary heart disease risk 
has been elusive. A variety of psychosocial factors are associ- 
ated with increased coronary heart disease risk. Best charac- 
terized is the so-called type A personality (94,95). However, 
years of study of type A behavior itself, and efforts to change 
that behavior, have not convincingly demonstrated that it 
changes coronary artery disease risk. Psychological stress and 
particularly the traits of depression and hostility are emerging 
as factors that reproducibly associate with an increase in 
coronary artery disease risk (96-98). Social factors that con- 
tribute to the relative isolation of individuals (such as lower 
educational level, economic insecurity and absence of family 
members or social contacts) are also related to increased 
coronary artery disease risk in observational studies (99,100). 
The mechanism by which psychological and social issues 
may influence coronary artery disease can be divided into two 
general categories: 1) direct mechanisms exerting their influ- 
ence through neuroendocrine effects, particularly by changes 
in brain catecholamine and serotonin levels and the brain's 
responsiveness; 2) indirect mechanisms influencing the pa- 
tient's adherence to preventive recommendations and compli- 
ance with therapeutic strategies. Recent data suggest that the 
two mechanisms may be linked. For example, it has been 
shown that serotonin-active drugs in selected (e.g., depressed) 
patients may enhance smoking cessation (101). 
The presence of major depression after acute myocardial 
infarction increases 6-month mortality more than and indepen- 
dent of such clinical factors as heart failure and extent of 
coronary disease (96,98). Hostility appears to have a particu- 
larly powerful influence on coronary artery disease outcome 
compared to other psychosocial factors (97,102). Patients 
without a "confidant" (spouse or other) have a threefold 
increase in 6-month mortality after acute myocardial infarction 
(99). Chronic stress, such as that produced by situations with 
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"high demand and low control" (103), doubles the risk of 
developing a myocardial infarction, even after controlling for 
other risk factors. Acute psychological stress may also increase 
risk of coronary artery disease vents (104). 
Interventions to improve psychosocial traits can improve 
adherence to medical regimens and enhance an individual's 
psychological state. Control of other risk factors can thereby be 
favorably influenced as well. Data from small prospective trials 
and from a meta-analysis of intervention trials also suggest that 
mortality and the frequency of recurrent events can be reduced 
(105,106). 
Triglyeerides. The relationship between serum triglyceride 
and coronary artery disease has been difficult to elucidate and 
remains controversial. Triglyceride levels uniformly predict 
coronary heart disease in univariate analyses but often lose 
their predictive power when other risk factors, particularly 
HDL cholesterol, are added in a multivariate analysis. Some 
have suggested that HDL cholesterol and triglycerides hould 
not be considered separately and that the combination of low 
HDL cholesterol and high triglycerides together is responsible 
for the marked increase in coronary artery disease risk when 
abnormalities of either alone are analyzed (107). When in- 
creased triglyceride levels are associated with increases in very 
LDL particles, high concentrations of "small, dense" LDL or 
high apolipoprotein B, the risk for coronary artery disease 
events is increased (108-110). 
This issue has become more complex with recognition of 
two important nonlipid associations ofhigh triglyceride l vels: 
1) Abnormalities of various clotting factors are also associated 
with hypertriglyceridemia (111). 2) In the syndrome that is 
variously known as syndrome X or familial dyslipidemic hyper- 
tension, high triglyceride levels, low HDL cholesterol, insulin 
resistance, abdominal adiposity and hypertension coexist and 
are metabolically inked (112). Patients with this constellation 
are relatively common, comprising an estimated 12% of all 
hypertensive patients (113,114), and are noted to have a 
markedly increased risk of coronary artery disease vents. 
Weight loss, dietary changes, including caloric restriction 
and a decrease in alcohol consumption, smoking cessation and 
physical activity all decrease triglyceride levels. However, it 
cannot be currently determined whether any reduction in risk 
resulting from these changes i  due to the triglyceride lowering 
itself. Several ipid-lowering studies have suggested that the 
greatest reduction in coronary artery disease mortality and 
events occurs with LDL cholesterol lowering in patients with 
elevated triglyceride levels (16,115). Thus, detection and re- 
duction of an elevated triglyceride level appears to be most 
important in patients at highest risk, particularly those with 
other risk factors, including an elevated LDL cholesterol and a 
decreased HDL cholesterol. 
A 1992 Consensus Development Conference defined 200 to 
400 mg/dl as "borderline high triglyceride," 400 to 1,000 mg/dl 
as "high triglyceride" and >1,000 mg/dl as "very high triglyc- 
eride" (116). Based on these definitions, the Adult Treatment 
Panel II has suggested a treatment algorithm for the athero- 
sclerosis-prone individual with elevated triglyceride l vels (15). 
Lipoprotein(a). Lipoprotein(a) [Lp(a)] is a lipoprotein 
particle consisting of an LDL molecule in which the major 
apoprotein of LDL, apo B100, is linked to an additional large 
protein designated apo(a) (117). Although Lp(a) was identi- 
fied and linked to coronary artery disease over 30 years ago, 
recent attention derives from both further epidemiologic evi- 
dence of this risk association and from recognition that apo(a) 
has structural homology with plasminogen, making Lp(a) a 
potential inhibitor of fibrinolysis (117,118). 
Lipoprotein(a) levels are not normally distributed. They are 
markedly skewed to the lower end of the range, and some 
individuals have virtually undetectable vels. Levels within 
populations vary 1,000-fold (119) and are independent ofother 
lipid levels. Lipoprotein(a) levels are largely genetically deter- 
mined through autosomal dominant inheritance (117). Among 
patients with premature coronary artery disease, 15% to 20% 
have elevated Lp(a) levels, making Lp(a) the most common 
inherited lipoprotein disorder associated with premature cor- 
onary disease (120). Lipoprotein(a) levels increase slightly with 
age, are higher in blacks than in whites and tend to be higher 
in women (121,122). Lipoprotein(a) levels increase by about 
8% in women after menopause (121). Diet does not appear to 
affect Lp(a) levels; however, both anabolic steroids and estro- 
gens reduce Lp(a), although the effect is highly variable 
(117,118,123). Among conventional lipid agents, only niacin 
lowers Lp(a) levels (117). 
The evidence that Lp(a) is a risk factor for coronary artery 
disease vents is based largely on retrospective observational 
studies (117,118). These findings, combined with laboratory 
investigations demonstrating a variety of proatherogenic ef- 
fects for Lp(a), have led to widespread interest in Lp(a) as an 
important risk factor (124). Large prospective study data are, 
however, controversial. Recently one study failed to demon- 
strate an association between Lp(a) and risk of myocardial 
infarction among men (119), whereas another supported the 
association between Lp(a) and coronary disease vents (125). 
No prospective interventional trial information is available to 
confirm the importance of Lp(a) in coronary disease. Further- 
more, issues of sample handling, risk in different populations 
and the relative importance of different Lp(a) isoforms will 
need to be addressed before the role of Lp(a) in coronary 
artery disease risk can be resolved. 
Homocysteine. Catabolism of the amino acid homocysteine 
is largely dependent on the enzyme cystathionine B-synthase, 
the complete absence of which leads to the childhood isease 
homocysteinuria and early mortality due in part to advanced 
arterial esions (126). Heterozygosity for the enzyme produces 
elevated homocysteine l vels in adulthood (126). Homocys- 
teine levels can also be increased by deficiencies of vitamins B 6 
and B12 or folate (127,128). Increased homocysteine levels are 
associated with increased risk of both coronary artery disease 
and peripheral arterial disease (126,129). Of patients identified 
with elevated homocysteine l vels, approximately two thirds 
appear to be associated with low levels of these vitamins (127). 
While prevalence information regarding increased homocys- 
teine levels is complex and incomplete, data from the elderly 
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cohort of the Framingham Heart Study population suggest that 
over 20% of this population has elevated homocysteine levels 
(127). Homocysteine-induced vascular damage may occur as a 
consequence of the amino acid's procoagulant activities or by 
direct injury of vascular endothelium (126). From both mech- 
anistic and epidemiologic points of view, bomocysteine ap- 
pears to be unrelated to other cardiovascular risk factors. 
The prevalence of hyperhomocysteinemia among patients 
with vascular disease varies from approximately 25% to 45%, 
depending on the age group studied (129). The risk of prema- 
ture occlusive vascular disease is 30 times greater for those 
with elevated levels than for normal control subjects (129). An 
elevated homocysteine level is associated with a 3.4-fold in- 
crease in 5-year myocardial infarction risk in a prospective 
study of participants in the Physician's Health Study (130). 
Because vitamin B6, vitamin B12 or folate supplements can 
reverse moderately elevated blood levels of homocysteine, 
prospective clinical trials have been proposed (131). 
Oxidative stress. Extensive laboratory data indicate that 
the oxidative modification of LDL cholesterol, particularly in 
the vessel wall, accelerates the atherogenic process (132,133). 
Oxidized LDL cholesterol may facilitate atherosclerotic dis- 
ease by recruiting monocyte macrophages, timulating auto- 
antibodies, stimulating LDL uptake by macrophages and in- 
creasing vascular tone and coagulability. Antioxidants, both in 
vivo and in vitro, can increase LDL resistance to oxidation and 
are associated with lower coronary artery disease risk in 
epidemiologic studies. Reports of antioxidant vitamin con- 
sumption as part of a regular diet have suggested that those 
diets high in vitamin C, vitamin E and beta-carotene are 
protective against coronary heart disease in both men and 
women (134-136). Many other dietary and nondietary factors 
may reduce LDL oxidation, including selenium, estrogen, 
flavonoids, magnesium and monounsaturated fat. Iron, copper, 
zinc and saturated fats all are likely to increase oxidative 
potential. 
Prospective observational studies uggest a powerful effect 
of antioxidant vitamin supplement consumption, particularly 
vitamin E, but results are inconsistent and may depend on 
baseline consumption ffoods with antioxidant potential or on 
the presence of other oxidative stresses uch as smoking 
(137,138). Although several small prospective interventional 
trials in animals and humans have suggested a benefit of 
vitamin supplements, the only large prospective randomized 
trial--the Finnish Alpha-Tocopherol Beta-Carotene Cancer 
Prevention Study--failed to lower coronary artery disease risk 
among middle-aged male smokers (139). Thus, although en- 
hanced dietary intake of foods with antioxidant potential is 
likely to be of benefit, the value of vitamin supplementation 
continues to be unresolved. Several prospective trial results are 
due in the near future (140). 
Alcoholic beverage consumption. Individuals reporting 
moderate amounts of alcohol intake (approximately one to 
three drinks daily) have a 40% to 50% reduction in coronary 
artery disease risk compared with individuals who are abstinent 
(141-143). Excessive consumption falcohol is associated with 
increased coronary disease risk (144), possibly resulting from 
misclassification f alcoholic ardiomyopathy as coronary heart 
disease or from alcohol's ability to produce hypertension a d 
to increase cardiac arrhythmias (145). In addition, excessive 
early alcohol intake can produce many other medical problems 
that can outweigh its beneficial effects on coronary artery 
disease risk. 
An alcohol-induced increase in HDL cholesterol accounts 
for approximately half of the reduction in myocardial infarc- 
tions associated with moderate alcohol intake. Alcohol appears 
predominantly to reduce the incidence of myocardial infarc- 
tion and sudden cardiac death and has less effect on the 
incidence of angina pectoris (143). This suggests hat alcohol's 
reduction in risk may be mediated by effects on vascular 
reactivity (146) or on hemostatic factors (147,148), thereby 
reducing acute events rather than reducing coronary athero- 
sclerosis progression. This concept is supported by limited 
autopsy data indicating that alcohol has little effect on coro- 
nary atherosclerosis among moderate drinkers (143) and by 
several angiographic studies documenting fewer coronary oc- 
clusions among moderate drinkers (149). 
It has been suggested that he reduction i  coronary disease 
risk associated with alcoholic beverages i due to the effect of 
alcohol alone. Several studies demonstrate similar reductions 
in risk for beer, wine and hard liquor (143,150), whereas wine 
alone accounts for most of the reduction i  risk in some studies 
(151,152), and beer may actually increase risk in others (152). 
Among populations with high cholesterol and saturated fat 
intake, wine consumption is more strongly related to reduced 
risk than total alcohol consumption, and wine intake might 
explain some of the decreased rate of coronary heart disease 
among the French despite their high saturated fat intake (151). 
Both red wine and grape juice inhibit platelet activity in vivo 
(147), lending credence to the idea that some derivative of red 
grapes is beneficial. Such observations raise the possibility that 
the alcohol-containing beverage itself may also influence cor- 
onary artery disease risk. 
Category IV. Risk Factors Associated With 
Increased Risk but Which Cannot Be 
Modified or Whose Modification Would Be 
Unlikely to Change the Incidence of 
Coronary Disease Events 
Although age, gender and family history are not modifiable, 
it is likely that all these factors exert their influence on 
coronary artery disease risk, at least in part through other risk 
factors noted previously. In Western populations, coronary 
artery disease risk increases nearly linearly with age and is 
greater in men compared to women until approximately age 
75, when the prevalence isnearly equal. Below 55 years of age, 
the incidence of coronary heart disease among men is three to 
four times that among women; after 55 years, the rate of 
increase with age in men declines and that in women continues 
to increase, so that incidence rates in men and women become 
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similar in older persons (153). The gender differential isgreatly 
attenuated in nonwhite populations and in populations with 
low coronary heart disease rates (154). In patients with known 
coronary artery disease, age is one of the most powerful 
predictive factors for death, although its relationship to non- 
fatal events has been less thoroughly evaluated. In the post- 
myocardial infarction setting, older patients are at higher 
subsequent risk of death than younger patients, and the effect 
of age predominates over other risk factors. 
Because coronary artery disease clusters in families, a 
family history of premature coronary heart disease is a risk 
factor. The National Cholesterol Education Program (NCEP) 
lists the family history of premature coronary heart disease 
high on their list of recognized risk factors (15). With increas- 
ing numbers of elderly patients, the high prevalence of coro- 
nary heart disease and increasing levels of therapeutic nter- 
vention in older patients, it is important to define "premature" 
in relation to the development of coronary heart disease. 
Although age is a continuous variable, cut points are useful; 
and for this purpose, the NCEP defines a family history of 
premature coronary heart disease as a definite myocardial 
infarction or sudden death before 55 years of age in a father or 
other male first-degree relative, or before 65 years of age in a 
mother or other female first-degree relative. 
Over a decade and a half ago, Hopkins and Williams (155) 
surveyed 246 "suggested coronary risk factors" from the 
literature. A similar survey undertaken today would most likely 
add dozens more. If the only criteria for identification of a 
"risk factor" is recognition of an association with coronary 
heart disease, then the total number of such factors would be 
enormous. Many factors cited in such reviews are often the 
source of much media and lay attention, including markers 
such as the ear lobe crease, premature baldness and height, to 
name a few. Although recognition of such factors may help to 
predict future coronary events, their modification is not likely 
to influence the course of an individual's vascular disease, and 
thus, for the purposes of the task of matching level of risk with 
level of management, they need not be considered further. 
Summary 
In matching management i ensity with cardiovascular risk, 
we proposed a scheme of categories of descending levels of 
evidence to support the benefit of direct management. That is, 
we began with those risk factors for which the most conclusive 
evidence xists and whose management favorably affects out- 
comes, and we ended with those factors for which management 
opportunities are minimal or absent or for which modification 
would not or could not alter the course of the disease. The 
proposed risk factor categories are as follows: 
I. Risk factors for which interventions have proved to 
reduce the incidence of coronary artery disease vents (ciga- 
rette smoking, LDL cholesterol, hypertension, thrombogenic 
factors). 
II. Risk factors for which interventions are likely, based on 
our current pathophysiologic understanding and on epidemi- 
ologic and clinical trial evidence, to reduce the incidence of 
coronary artery disease events (diabetes, physical inactivity, 
HDL cholesterol, obesity, postmenopausal tatus). 
III. Risk factors clearly associated with an increase in 
coronary artery disease risk and which, if modified, might lower 
the incidence of coronary artery disease vents (psychosocial 
factors, triglycerides, Lp(a), homocysteine, oxidative stress, 
alcohol consumption). 
IV. Risk factors associated with increased risk but which 
cannot be modified or whose modification would be unlikely to 
change the incidence of coronary disease vents (age, gender, 
family history and many others). 
Dietary modification is important throughout the course of 
evaluation and management of many of the major isk factors. 
Therefore, "diet" has not been included in the list of risk 
factors as categorized in this task force. Rather, we recognize 
that diet interacts with different risk factors at many different 
levels. If diet were to be included, it would qualify for category 
I status. 
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